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ABSTRACT
Objective: To evaluate the anti-inflammatory activity of sodium valproate and docosahexaenoic acid (DHA) supplementation using various 
experimental models in albino Wistar rats.
Method: A total of 48 adult Wistar albino male rats were divided into 8 groups of 6 rats each. Group I was control (distilled water 1 ml/kg), Group II 
received intraperitoneal (i.p.) injection of indomethacin (10 mg/kg), Groups III-V were injected (i.p.) with sodium valproate 100, 200, and 400 mg/kg 
water, and Groups VI-VIII were given sodium valproate 100, 200, and 400 mg/kg plus DHA 300 mg/kg (i.p.), respectively. Anti-inflammatory activity 
was assessed using carrageenan induced paw edema and the cotton pellet granuloma models.
Results: We found that higher doses of sodium valproate (400 mg/kg) used either alone or with a combination of DHA (300 mg/kg) showed a 
significant anti-inflammatory activity when compared to control in both the models of inflammation.
Conclusion: Combination of sodium valproate along DHA has shown promising anti-inflammatory activity.
Keywords: Anti-inflammatory drugs, Sodium valproate, Rat model.
INTRODUCTION
Nonsteroidal anti-inflammatory drugs (NSAIDs) that include both 
traditional cyclooxygenase (COX) inhibitors and the newer selective 
(COX-2) ones are at present the mainstay drugs for treating pain and 
inflammation. While at one end there is no doubt that these drugs 
are effective in the management of conditions such as ankylosing 
spondylitis, osteoarthritis, and rheumatoid arthritis, on the other hand, 
they are known to cause adverse effects. While traditional agents are 
known to cause gastrointestinal adverse effects with chronic use, the 
COX-2 inhibitors possess a cardiotoxic potential [1].
Corticosteroids are known to possess anti-inflammatory and immune 
modulatory effects. Like NSAIDs, they are useful in the management 
of painful inflammatory conditions such as rheumatoid arthritis and 
gout [2]. However, they cause gastritis, proximal muscle weakness, 
diabetes, and they predispose to infections [3].
The quest for an ideal anti-inflammatory, which is effective and nontoxic 
at the same time, has got the researchers thinking. Various avenues 
have been explored.
A commonly used antiepileptic drug, sodium valproate has 
been found to be effective in many nonepileptic conditions like 
bipolar disorder and migraine prophylaxis, thanks to its multiple 
mechanisms of action [4]. One such mechanism of action is inhibition 
of histone deacetylation (HDAC). It is reported that valproate has 
neuroprotective and anti-inflammatory properties due to HDAC 
inhibition [5].
Omega-3 fatty acids, such as eicosapentaenoic acid and the DHA, have 
shown to decrease the risk of developing many diseases such as cancer, 
hypertension, and cardiac disease. They have been shown to compete 
against arachidonic acid for lipooxygenase and COX thereby preventing 
production of proinflammatory mediators. In addition, this being a 
natural product is less likely to cause adverse effects compared to the 
traditional anti-inflammatory drugs [6]. In view of these reports, a 
study was initiated with a plan to assess the effect of sodium valproate 
alone and in combination with DHA in rat models of inflammation.
METHODS
An in vivo experimental study conducted in the Department of 
Pharmacology, Kasturba Medical College, Manipal University, Manipal, 
Karnataka, India.
Selection and animal handling
A total of 48 adult Wistar albino healthy rats were selected for this 
study, which were locally bred in the Central Animal House of Manipal 
University, Manipal. These animals weighed 150-200 g and they were 
around 6 months old and were housed under controlled conditions 
with temperature of about 23±2°C, 50±5% humidity, and 10-14 hr 
of light and dark cycle, respectively. These animals were individually 
housed in polypropylene cages which contained paddy husk (procured 
locally) which was sterile, as bedding throughout the study and had 
easy access to animal chow (sterile food) and water ad libitum. This 
study was initiated after taking approval from the Institutional Animal 
Ethics Committee (IAEC/KMC/75/2014 dated August 22, 2014). The 
experiments were conducted in accordance to CPCSEA guidelines.
Identification of individual animals
Rats from each treatment group were marked using different colored 
marks on their tails, for easy identification and experimentation, 
according to the group allotted.
Drugs, reagents, and other materials
Three drugs were used during the study. Indomethacin, sodium 
valproate, and DHA were used. The pure powder form was used, 
dissolved in distilled water.
Evaluation of anti-inflammatory activity
A total of 48 adult Wistar albino male rats weighing 150-200 g were 
equally divided into 8 groups of six rats each. The rats were weighed 
and marked. Group I was taken as the control (distilled water 1 ml/kg), 
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Group II was given indomethacin injection (10 mg/kg) intraperitoneal 
(i.p.), Group III-V, were injected (i.p.) with sodium valproate 100, 200, 
and 400 mg/kg dissolved in distilled water, and Group VI-VIII were 
given sodium valproate 100, 200, and 400 mg/kg dissolved with 
distilled water along with DHA 300 mg/kg (i.p.), respectively. The 
dose of sodium valproate was chosen as 100 mg/kg, 200 mg/kg, and 
400 mg/kg based on a study performed by Raza et al. [7]. The dose of 
DHA was chosen as 300 mg/kg based on a study done by Gao et al. [8]
Carrageenan-induced paw edema model
The plethysmometer is a device used to measure small changes in 
volume. Two interconnected Perspex tubes form the volume transducer 
and these tubes are filled with conductive solution. The displacement 
produced as a result of object immersion in the measuring tube is 
measured in the second tube in between the platinum electrodes.
The albino Wistar rats were starved overnight. The test drug was 
administered. At 30 minutes post administration of test or reference drug, 
each animal received 0.1 ml of 1% carrageenan subcutaneously in the 
hind paw of the right side. The left paw was then injected subcutaneously 
with the same volume of distilled water. Following this, the volume of the 
paw was measured using plethysmometer by the volume displacement 
technique which was sensitive to a volume change of 0.01 ml. The paw 
volume was measured pretreatment and post-treatment at 60 minutes 
gap at 60, 120, 180, and 240 minutes. The difference in the paw 
volume was then measured and values tabulated. Percent inhibition of 
inflammation was then calculated using the formula:
Percent inhibition=[1-(A-B/C-D)]*100.
Where A and B were the mean paw volume of the rats before and after 
injection of carrageenan, respectively, in the test group, and C and D are 
the mean paw volume of rats before and after carrageenan injection, 
respectively, in the control group [9].
Cotton pellet granuloma model
The albino Wistar rats were weighed and marked. A sterile cotton pellet 
was weighed, and 30 mg was placed in the subcutaneous plane in the groin 
of rats. Group I was taken as a control (distilled water 1 ml/kg), Group II was 
be given an (i.p.) injection of indomethacin (10 mg/kg), Groups III-V were 
injected (i.p.) with sodium valproate 100, 200, and 400 mg/kg dissolved 
with distilled water, and Groups VI-VIII were given sodium valproate 
100, 200, and 400 mg/kg dissolved with distilled water along with DHA 
300 mg/kg, respectively, once daily for seven consecutive days. On day 8, 
the rats were sacrificed by overdose of ketamine (80 mg/kg; i.p.) followed 
by cervical dislocation and cotton pellets were removed. Extraneous tissue 
was separated following, which the pellets were dried overnight at a 
temperature of 60°C to a constant weight. Any increase in the weight of the 
pellet was taken as deposition of granuloma tissue [10].
A washout period of 1-month was maintained after studying each 
inflammation models.
Statistical analysis
The data obtained were analyzed using IBM statistical package for social 
sciences version 22.0. The results were expressed as mean±standard 
error of mean. The significance of difference within the groups at 
different end points was assessed using repeated measures one-way 
analysis of variance (ANOVA). Similarly, the significance of differences 
between the various groups were checked for using ANOVA, followed by 
post hoc Tukey’s test. Importantly, all test groups were compared against 
the control and standard groups, to arrive at a conclusion regarding the 
results. P <0.05 was considered to be statistically significant.
RESULTS
Anti-inflammatory activity
1. Carrageenan-induced paw edema model
The paw volume was significantly lower (0.23±0.05, p=0.010, % inhibition 
- 58.93%) in the indomethacin (10 mg/kg) treated group, 0.11±0.03, 
p<0.001, % inhibition - 80.36% in sodium valproate (100 mg/kg) plus 
DHA (300 mg/kg) group, 0.15±0.03, p=0.001, % inhibition - 73.22% in 
the sodium valproate (200 mg/kg) plus DHA (300 mg/kg) group, and 
0.16±0.04, p=0.001, % inhibition - 71.43% in the sodium valproate 
(400 mg/kg) plus DHA (300 mg/kg) group at 60 minutes when compared 
to control (0.56±0.08) as shown in Table 1 and Fig. 1.
The paw volume was significantly lower (0.34±0.06, p<0.001, % 
inhibition - 68.81%) in the indomethacin (10 mg/kg) treated group, 
0.53±0.26, p=0.015, % inhibition - 51.38% in sodium valproate 
(200 mg/kg) group, 0.46±0.13, p=0.005, % inhibition - 57.80% 
in sodium valproate (400 mg/kg) group, 0.31±0.06, p<0.001, % 
inhibition - 71.56% in sodium valproate (100 mg/kg) plus DHA 
(300 mg/kg) group, 0.32±0.06, p<0.001, % inhibition - 70.65% in the 
sodium valproate (200 mg/kg) plus DHA (300 mg/kg) group, and 
0.25±0.05, p<0.001, % inhibition - 77.07% in the sodium valproate 
(400 mg/kg) plus DHA (300 mg/kg) group at 120 minutes when 
compared to control (1.09±0.16) as shown in Table 1 and Fig. 1.
The paw volume was significantly lower (0.39±0.06, p<0.001, % 
inhibition - 73.65%) in the indomethacin (10 mg/kg) treated group, 
0.93±0.1, p=0.001, % inhibition - 37.17% in sodium valproate 
(100 mg/kg) group, 0.63±0.16, p<0.001, % inhibition - 57.44% 
in sodium valproate (200 mg/kg) group, 0.31±0.06, p<0.001, % 
inhibition - 79.06% in sodium valproate (400 mg/kg) group, 0.38±0.06, 
p<0.001, % inhibition - 74.33% in sodium valproate (100 mg/kg) plus 
DHA (300 mg/kg) group, 0.40±0.07, p<0.001, % inhibition - 72.98% in 
the sodium valproate (200 mg/kg) plus DHA (300 mg/kg) group, and 
0.34±0.06, p<0.001, % inhibition - 77.03% in the sodium valproate 
(400 mg/kg) plus DHA (300 mg/kg) group at 180 minutes when 
compared to control (1.48±0.06) as shown in Table 1 and Fig. 1.
The paw volume was significantly lower (0.41±0.04, p<0.001, % 
inhibition - 72.85%) in the indomethacin (10 mg/kg) treated group, 
0.89±0.28, p=0.037, % inhibition - 41.06% in sodium valproate 
(100 mg/kg) group, 0.29±0.03, p<0.001, % inhibition - 80.80% 
in sodium valproate (400 mg/kg) group, 0.57±0.06, p<0.001, % 
Fig. 1: Anti-inflammatory activity of sodium valproate and 
docosahexaenoic acid in carrageenan-induced paw edema model, 
mean difference in paw volume (mL) ± Standard error of mean 
at different time points. b denotes p<0.05 compared to control 
p value obtained by one-way analysis of variance followed by 
post hoc Tukey’s test
Asian J Pharm Clin Res, Vol 10, Issue 1, 2017, 286-289
 Kunder et al. 
288
inhibition - 62.26% in sodium valproate (100 mg/kg) plus DHA 
(300 mg/kg) group, 0.45±0.11, p<0.001, % inhibition - 70.20% in the 
sodium valproate (200 mg/kg) plus DHA (300 mg/kg) group, and 
0.35±0.05, p<0.001, % inhibition - 76.83% in the sodium valproate 
(400 mg/kg) plus DHA (300 mg/kg) group at 240 minutes when 
compared to control (1.51±0.06) as shown in Table 1 and Fig. 1.
2. Cotton pellet granuloma
As shown in Table 2 and Fig. 2, the dry weight of cotton pellet granuloma 
in control group was 0.13±0.01 g, in indomethacin (10 mg/kg) group 
was 0.03±0.00 g (p<0.001), in sodium valproate (100 mg/kg) group was 
0.13±0.01 g (p=1.000), in sodium valproate (200 mg/kg) group 
was 0.13±0.01 g (p=1.000), in sodium valproate (400 mg/kg) group 
was 0.07±0.02 g (p<0.001), in sodium valproate (100 mg/kg) plus 
DHA (300 mg/kg) group was 0.08±0.03 g (p=0.001), sodium valproate 
(200 mg/kg) plus DHA (300 mg/kg) group was 0.06±0.03 g (p<0.001), 
and sodium valproate (400 mg/kg) plus DHA (300 mg/kg) group was 
0.07±0.02 g (p<0.001). The drug sodium valproate when given alone 
in low doses (100 and 200 mg/kg) did not show any statistically 
significant anti-inflammatory property when compared to control. 
However, 400 mg/kg of sodium valproate when given alone showed 
statistically significant anti-inflammatory activity when compared to 
control. All the three groups where sodium valproate was combined 
with DHA showed statistically significant anti-inflammatory activity as 
compared to control. However, the reduction in granuloma formation in 
these groups was less than that of standard drug indomethacin.
DISCUSSION
The anti-inflammatory action of sodium valproate along with DHA 
was assessed using cotton pellet granuloma as well as paw edema 
model induced by Irritant carrageenan which are standard models 
for screening agents for anti-inflammatory activity. Paw edema model 
with carrageenan in rats is the standard model to evaluate acute 
inflammation. Carrageenan is the irritant that is preferred for testing 
drugs for anti-inflammatory activity as it is nonantigenic and also due 
to the absence of systemic effects. It induces edema in two phases; the 
first phase is characterized by serotonin release and also the release of 
kinins and histamine, whereas the second phase is due to the release of 
prostaglandins and slow reacting substances.
In the carrageenan induced paw edema model, a combination of 
sodium valproate all three doses used with 300 mg of DHA showed 
anti-inflammatory activity compared to control at 60 minutes. 
Sodium valproate 200 mg, sodium valproate 400 mg, combination of 
sodium valproate 100mg with 300 mg of DHA, combination of sodium 
valproate 200 mg with 300 mg of DHA, and combination of sodium 
valproate 400 mg with 300 mg of DHA showed anti-inflammatory 
activity compared to control at 120 minutes. Sodium valproate 100 mg, 
sodium valproate 200 mg, sodium valproate 400 mg, combination of 
sodium valproate 100 mg with 300 mg of DHA, combination of sodium 
valproate 200 mg with 300 mg of DHA, and combination of sodium 
valproate 400 mg with 300 mg of DHA showed anti-inflammatory 
activity compared to control at 180 and 240 minutes. The similar 
anti-inflammatory activity of sodium valproate was reported by earlier 
workers [7].
In the cotton pellet granuloma model, sodium valproate given alone at 
400 mg, combination of sodium valproate 100 mg with 300 mg of DHA, 
combination of sodium valproate 200 mg with 300 mg of DHA, and 
combination of sodium valproate 400 mg with 300 mg of DHA showed 
anti-inflammatory activity as compared to control. However, the anti-
inflammatory activity was less than that of standard drug indomethacin.
The carrageenan injection into the paw of the rat is said to raise the 
levels of interleukin 6 (IL-6), IL-1 β, tumor necrosis factor alpha (TNF α), 
and cytokine-induced neutrophil chemoattractant 1 levels [11]. In 
addition, nitric oxide is also involved in the carrageenan-induced 
inflammation. Sodium valproate, an HDACI inhibits the cytokines like 
Table 1: Carrageenan-induced paw edema model
Group Mean difference in paw volume (ml.)±SEM at different time points (percentage inhibition of edema)
60 minutes 120 minutes 180 minutes 240 minutes
Control 0.56±0.08 (0) 1.09±0.16 (0) 1.48±0.06 (0) 1.51±0.06 (0)
Indomethacin 10 mg/kg (std) 0.23±0.05b (58.93) 0.34±0.06b (68.81) 0.39±0.06b (73.65) 0.41±0.04b (72.85)
Val 100 mg/kg 0.53±0.11 (5.36) 0.78±0.10 (28.45) 0.93±0.11b (37.17) 0.89±0.28b (41.06)
Val 200 mg/kg 0.31±0.03 (44.65) 0.53±0.26b (51.38) 0.63±0.16b (57.44) 0.98±0.18 (35.10)
Val 400 mg/kg 0.32±0.05 (42.86) 0.46±0.13b (57.80) 0.31±0.06b (79.06) 0.29±0.03b (80.80)
Val 100 mg/kg+DHA 300 mg/kg 0.11±0.03b (80.36) 0.31±0.06b (71.56) 0.38±0.06b (74.33) 0.57±0.06b (62.26)
Val 200 mg/kg+DHA 300 mg/kg 0.15±0.03b (73.22) 0.32±0.06b (70.65) 0.40±0.07b (72.98) 0.45±0.11b (70.20)
Val 400 mg/kg+DHA 300 mg/kg 0.16±0.04b (71.43) 0.25±0.05b (77.07) 0.34±0.06b (77.03) 0.35±0.05b (76.83)
All values are expressed as Mean±SEM. bp<0.05 compared to control. p value obtained by one-way ANOVA followed by post hoc Tukey’s test. SEM: Standard error of 
mean
Table 2: Cotton pellet granuloma model
Groups Mean dry weight of 
granuloma (mg)
Control 0.13±0.01
Indomethacin 10 mg/kg (std) 0.03±0.00b
Val 100 mg/kg 0.13±0.01c
Val 200 mg/kg 0.13±0.01c
Val 400 mg/kg 0.07±0.02b
Val 100 mg/kg+DHA 300 mg/kg 0.08±0.03bc
Val 200 mg/kg+DHA 300 mg/kg 0.06±0.03b
Val 400 mg/kg+DHA 300 mg/kg 0.07±0.02bc
All values are expressed as Mean±SEM. bp<0.05 compared to control and 
cp<0.05 compared to standard. p value obtained by one-way ANOVA followed by 
post hoc Tukey’s test.  SEM: Standard error of mean, DHA: Docosahexaenoic acid
Fig. 2: Anti-inflammatory activity of sodium valproate and 
docosahexaenoic acid on cotton pellet granuloma model, mean dry 
weight of granuloma (mg). b denotes p<0.05 compared to control 
and c denotes p<0.05 compared to standard p value obtained by 
one-way analysis of variance followed by post hoc Tukey’s test
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IL-6 and TNF α. Migration of leukocytes to the inflammatory site is also 
inhibited [12]. Sodium valproate is also an antioxidant and inhibits the 
production of reactive oxygen species [13]. These effects of sodium may 
be responsible for its anti-inflammatory activity.
Studies were done by Ferrucci et al. have shown that there exists a 
reciprocal connection in between the omega-3 fatty acids levels and the 
inflammatory cytokines like TNF α and IL-6 and C-reactive protein [14]. 
Another study was done by Rao et al. in omega-3 fatty acid deficient rats 
has shown up-regulation of enzyme which converts arachidonic acid 
to prostaglandin E2 in these rats [15]. A study was done by McNamara 
et al. have shown that deficiency of omega-3 fatty acids increases the 
central serotonin turnover [16].
DHA suppresses nuclear factor Kappa Beta mediated nuclear 
translocation thereby inhibiting cytokine (TNFα, vascular endothelial 
growth factor, and IL-1β) mediated adhesion molecule expression [17]. 
DHA is also a peroxisome proliferator activated receptor gamma 
activator. In addition, they produce resolvins and protectins through 
pathways involving lipoxygenase and COX enzymes, which have an 
anti-inflammatory role. These protectins and resolvins prevent the 
neutrophilic infiltration by preventing transendothelial migration [18]. 
All these effects probably contribute to the anti-inflammatory effects.
In conclusion, the combination of sodium valproate and DHA has 
shown better anti-inflammatory activity. A well planned clinical trial 
using this combination may be worthwhile to evaluate the possibility 
its therapeutic use in various inflammatory conditions.
CONCLUSION
Higher doses of sodium valproate, either used alone or along with DHA 
showed statistically significant anti-inflammatory activity in both the 
models of inflammation. The combination of sodium valproate and 
DHA has shown promising anti-inflammatory activity and was almost 
comparable to standard drugs used in this study. Clinical studies on this 
combination may be worthwhile.
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